SCHEMBL1008926

SCHEMBL1008926

O=C(O)[C@H](Cc1ccc(O)cc1)NF

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.56
NAALAD2 Q9Y3Q0 1/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ACE P12821 7/20 0.55
SLC7A5 Q01650 1/20 0.55
MME P08473 6/20 0.52
CPA1 P15085 1/20 0.51
ACE2 Q9BYF1 1/20 0.51
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
ALB P02768 1/20 0.46
IL2 P60568 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008925 1.00 FOLH1 (0.56) FOLH1NAALAD2MEN1KMT2AL3MBTL1
SCHEMBL22290826 0.85 ALDH1A1 (0.57) FOLH1KMT2AACEMMECPA1
SCHEMBL29964738 0.85 ALDH1A1 (0.57) FOLH1KMT2AACEMMECPA1
SCHEMBL144008 0.85 MME (0.57) FOLH1NAALAD2L3MBTL1ACESLC7A5
SCHEMBL199980 0.85 MME (0.57) FOLH1NAALAD2L3MBTL1ACESLC7A5
SCHEMBL31345792 0.85 MME (0.57) FOLH1NAALAD2L3MBTL1ACESLC7A5
SCHEMBL144009 0.85 MME (0.57) FOLH1NAALAD2L3MBTL1ACESLC7A5
SCHEMBL22290975 0.84 FPR2 (0.54) FOLH1NAALAD2MEN1KMT2AL3MBTL1
SCHEMBL22290683 0.84 ADAMTS5 (0.54) KMT2ACA2
SCHEMBL22290939 0.84 FPR2 (0.54) MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117337295-A Bicyclic peptide ligands specific for TREM2 拜斯科技术开发有限公司 2024-01-02 CN claimed
EP-3558395-A1 TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION The Johns Hopkins University (US) 2019-10-30 EP claimed
CN-110366432-A Tumour and immunocyte imaging based on PD-L1 expression 约翰霍普金斯大学 2019-10-22 CN claimed
US-20190314531-A1 TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION THE JOHNS HOPKINS UNIVERSITY 2019-10-17 US claimed
CN-109295025-A The protein photo induced electron transfer fluorescent optical sensor protein family of Tyrosine Analogues translation system and gene coding 中国科学院生物物理研究所 2019-02-01 CN claimed
WO-2018119313-A1 TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION THE JOHNS HOPKINS UNIVERSITY (US) 2018-06-28 WO claimed
CN-102516003-A Methods for the purification of radiolabelled products using a solid-support scavenger HAMMERSMITH IMANET LTD 2012-06-27 CN claimed
CN-102333536-A Ss-arrestin effectors and compositions and methods of use thereof TREVENA INC 2012-01-25 CN claimed
CN-102132280-A Model enhanced imaging KONINKL PHILIPS ELECTRONICS NV 2011-07-20 CN claimed
EP-2032711-A1 HOST CELLS AND USES THEREOF IN THE MICROBIAL PRODUCTION OF HYDROXYLATED AROMATICS Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO (NL) 2009-03-11 EP claimed
WO-2007133084-A1 HOST CELLS AND USES THEREOF IN THE MICROBIAL PRODUCTION OF HYDROXYLATED AROMATICS NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 2007-11-22 WO claimed
US-20050214776-A1 Aequorin and obelin mutants with differing wavelengths and bioluminescence UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2005-09-29 US claimed
JP-3188002-A None JP disclosed
US-12637494-B2 Method for producing peptide containing non-natural amino acid CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-05-26 US disclosed
EP-4713675-A1 ELECTROCHEMICAL METHOD AND SENSOR FOR PFAS DETECTION B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University (IL) 2026-03-25 EP disclosed
US-20250340916-A1 METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-11-06 US disclosed
WO-1995033843-A1 DEBLOCKING THE COMMON PATHWAY OF AROMATIC AMINO ACID SYNTHESIS PURDUE RESEARCH FOUNDATION (US) 1995-12-14 WO disclosed
WO-1995014710-A1 CHEMICALLY MODIFIED BINDING PROTEIN YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) 1995-06-01 WO disclosed
JP-H03188002-A PRESERVATIVE FOR CUT FLOWER SUMITOMO CHEM CO LTD 1991-08-16 JP disclosed
US-4925651-A TUMOR DIAGNOSIS KERNFORSCHUNGSANLAGE JUELICH GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1990-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637494-B2 Method for producing peptide containing non-natural amino acid MRPL21, RPL21, RPL30 FOLH1 2856/4885NAALAD2 1127/4885MEN1 3529/4885
US-20190314531-A1 TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION CD274, PDCD1LG2, PDCD1 FOLH1 276/4885NAALAD2 2292/4885MEN1 673/4885
US-20250340916-A1 METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM AARS1, NSUN3, RNGTT FOLH1 1210/4885NAALAD2 835/4885MEN1 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.